RE:RE:RE:RE:RE:RE:RE:RE:RE:Addressable market They will not be out of cash but they will be in an uncomfortable spot with cash. I am guessing they will have less than $20 million in cash starting in July ($29 million to start Q2, $3 million in estimated Q2 negative cash flow, $1 million in estimated negative June cash flow, $20 million loan from Marathon and $28 million in estimated principle and interest payments on the convert leaving them with an estimated $17 million. That is enough to get them to the point where they are supposed to be cash flow positive but it is certainly uncomfortable. If they can somehow get some good early TH-1902 results, maye they can get some partnership cash as well but I am not betting on that. It also assumes there are no unusual expenses that arise.
If TH-1902's early revised phase 1b trial results don't show promise, they likely shut it down and are quickly profitable. If TH-1902's revised trial does show good results, then it is a question of how good and how quickly they can monetize it via either partnership or share sales at a higher stock price.
The big cash crunch comes in July of 2024 when they need to start making the principal repayments onthe Marathon loan. If TH-1902 is shut down by then and sales of Trogarzo and Egrifta are going along reasonably well, maybe they can make those payments as there would undoubtedly be a lot of cost cuts if TH-1902 fails in the clinic (including the high priced CEO and likely other senior staff who might leave for greener pastures).
If TH-1902 really works, then obtaining the needed funds will not be all that difficult.
That is how I see it but perhaps others have other good input into this situation.
As for selling the company, I don't guessing there are not many buyers for Egrifta and Trogarzo and TH-1902 is still unproven. If TH-1902 is shown to work, however, the buyout option becomes pretty real and we are likely to get less than we should in that scenario but it would still be a lot more than the current share price.
Trogarzon wrote: That's why I think they need to sell the company to a deep pocket comany to improve sales of their producs. They have no money left after the debenture gets paid next month. Otherwise like our Chairwomen supposibly said Th1902 is the key to higher stockprice. No that's a hail mary in my book. Shure go ahead put the house on number 1902 and pray.